Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002946 · ClinicalTrials.gov registry record · Phase 1
Penclomedine in Treating Patients With Solid Tumors or Lymphoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00002946: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00002946 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002946, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of penclomedine in treating patients with malignant solid tumors or lymphomas. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Interventions
- DRUG penclomedine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1997-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002946
The ClinicalTrials.gov registry entry for NCT00002946 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which penclomedine is the first listed.
NCT00002946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002946 about?
NCT00002946 is a clinical study titled "Penclomedine in Treating Patients With Solid Tumors or Lymphoma". Phase I trial to study the effectiveness of penclomedine in treating patients with malignant solid tumors or lymphomas. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00002946?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 1997-10.
What interventions are being tested in trial NCT00002946?
The interventions under investigation include: penclomedine (DRUG).
Who is sponsoring clinical trial NCT00002946?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.